Description
Homoharringtonine is an alkaloid found in Cephalotaxus that binds the A site of the 60 S ribosomal subunit, preventing aminoacyl-tRNA binding, inhibiting protein translation, and inducing cell death; it exhibits anticancer chemotherapeutic and immunosuppressive activities. Homoharringtonine is clinically used to treat chronic myelogenous leukemia (CML) and is currently in clinical trials as a potential treatment for acute myelogenous leukemia (AML) and myelodysplastic syndrome. In clinical subjects, homoharringtonine decreases the number of CD34+, CD117+ cells.
References
Gandhi V, Plunkett W, Cortes JE. Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia. Clin Cancer Res. 2014 Apr 1;20(7):1735-40. PMID: 24501394.
Daver N, Vega-Ruiz A, Kantarjian HM, et al. A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome. Eur J Cancer Care (Engl). 2013 Sep;22(5):605-11. PMID: 23701251.
Li YF, Deng Z, Din BH, et al. Effect of homoharringtonine on bone marrow CD34 + CD117 + cells in patients with chronic myelogenous leukemia. Leuk Lymphoma. 2012 May;53(5):934-9. PMID: 22054289.
